Business Wire

TII

13.5.2024 15:37:31 CEST | Business Wire | Press release

Share
Falcon 2: UAE’s Technology Innovation Institute Releases New AI Model Series, Outperforming Meta’s New Llama 3

The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today launched a second iteration of its renowned large language model (LLM) – Falcon 2. Within this series, it has unveiled two groundbreaking versions: Falcon 2 11B, a more efficient and accessible LLM trained on 5.5 trillion tokens with 11 billion parameters, and Falcon 2 11B VLM, distinguished by its vision-to-language model (VLM) capabilities, which enable seamless conversion of visual inputs into textual outputs. While both models are multilingual, notably, Falcon 2 11B VLM stands out as TII's first multimodal model – and the only one currently in the top tier market that has this image-to-text conversion capability, marking a significant advancement in AI innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513516248/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Falcon Image Caption Generator (Photo: AETOSWire)

Tested against several prominent AI models in its class among pre-trained models, Falcon 2 11B surpasses the performance of Meta’s newly launched Llama 3 with 8 billion parameters (8B), and performs on par with Google’s Gemma 7B at first place (Falcon 2 11B: 64.28 vs Gemma 7B: 64.29), as independently verified by Hugging Face, a US-based platform hosting an objective evaluation tool and global leaderboard for open LLMs. More importantly, Falcon 2 11B and 11B VLM are both open-source, empowering developers worldwide with unrestricted access. In the near future, there are plans to broaden the Falcon 2 next-generation models, introducing a range of sizes. These models will be further enhanced with advanced machine learning capabilities like 'Mixture of Experts' (MoE), aimed at pushing their performance to even more sophisticated levels.

All of TII’s AI models released to date have consistently ranked in the top tier globally, as the most powerful open-source LLMs. The new scaled-down and versatile Falcon 2 11B models are set to give TII greater market adoption in the ever-evolving world of generative AI.

Falcon 2 11B models, equipped with multilingual capabilities, seamlessly tackle tasks in English, French, Spanish, German, Portuguese, and various other languages, enriching their versatility and magnifying their effectiveness across diverse scenarios. Falcon 2 11B VLM, a vision-to-language model, has the capability to identify and interpret images and visuals from the environment, providing a wide range of applications across industries such as healthcare, finance, e-commerce, education, and legal sectors. These applications range from document management, digital archiving, and context indexing to supporting individuals with visual impairments. Furthermore, these models can run efficiently on just one graphics processing unit (GPU), making them highly scalable, and easy to deploy and integrate into lighter infrastructures like laptops and other devices.

H.E. Faisal Al Bannai, Secretary General of ATRC and Strategic Research and Advanced Technology Affairs Advisor to the UAE President, said: "With the release of Falcon 2 11B, we've introduced the first model in the Falcon 2 series. While Falcon 2 11B has demonstrated outstanding performance, we reaffirm our commitment to the open-source movement with it, and to the Falcon Foundation. With other multimodal models soon coming to the market in various sizes, our aim is to ensure that developers and entities that value their privacy have access to one of the best AI models to enable their AI journey."

Speaking on the model, Dr. Hakim Hacid, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: “AI is continually evolving, and developers are recognizing the myriad benefits of smaller, more efficient models. In addition to reducing computing power requirements and meeting sustainability criteria, these models offer enhanced flexibility, seamlessly integrating into edge AI infrastructure, the next emerging megatrend. Furthermore, the vision-to-language capabilities of Falcon 2 open new horizons for accessibility in AI, empowering users with transformative image to text interactions.”

The versatility of Falcon 2 11B has also led TII to consider working on more exciting GenAI innovations. Among these will be the adoption of a new type of machine learning capability known as the aforementioned ‘Mixture of Experts’. This method involves amalgamating smaller networks with distinct specializations, ensuring that the most knowledgeable domains collaborate to deliver highly sophisticated and customized responses – almost like having a team of smart helpers who each know something different and work together to predict or make decisions when needed. This approach not only improves accuracy, but it also accelerates decision-making, paving the way for more intelligent and efficient AI systems.

Falcon 2 11B is licenced under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.

Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513516248/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye